Merck & Co., Inc. is 2.6x more valuable than Bristol-Myers Squibb Company by market capitalization ($294.13 B vs $113.54 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BMY | MRK |
|---|---|---|
| Market cap | $113.54 B | $294.13 B |
| US-listed rank | #132 | #44 |
| Revenue (latest FY) | $48.19B | $65.01B |
| Net income (latest FY) | $7.05B | $18.25B |
| Net margin | 14.6% | 28.1% |
| P/E (trailing FY) | 16.1 | 16.1 |
| SEC filings | 1,000 | 996 |
Merck & Co., Inc. is 2.6x more valuable than Bristol-Myers Squibb Company by market capitalization ($294.13 B vs $113.54 B).
In their latest fiscal years, Bristol-Myers Squibb Company reported $48.19B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Bristol-Myers Squibb Company and Merck & Co., Inc., or browse the full rankings.